Treatment of multiple sclerosis patients with interferon-β primes monocyte-derived macrophages for apoptotic cell death

Journal of Leukocyte Biology

Volumn 70, Issue 5, 2001, Pages 745-748

  Van Weyenbergh, Johan ^a,b   Wietzerbin, Juana ^a   Rouillard, Dany ^a   Barral Netto, Manoel ^b   Liblau, Roland ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

CD 14; CD 64; CD 95 (Fas); In vivo

Indexed keywords

BETA1A INTERFERON; FAS ANTIGEN; LIPOCORTIN 5;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL STIMULATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHARMACOLOGY; IN VITRO STUDY; MACROPHAGE ACTIVATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BINDING; STAINING;

ADULT; ANNEXIN A5; ANTIGENS, CD95; APOPTOSIS; BIOLOGICAL RESPONSE MODIFIERS; CELL LINEAGE; FEMALE; HUMANS; INTERFERON-BETA; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS;

EID: 0035209939     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
2. Intramuscular IFN-β-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG)
3. Placebo-controlled multicentre randomised trial on interferon beta-1b in treatment of secondary progressive multiple sclerosis
4. Beta-interferon and multiple sclerosis
5. Recent advances in immunology in multiple sclerosis
6. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain
7. Interferon-β1b augments activation-induced T-cell death in multiple sclerosis patients
8. Indictment of the microglia as the villain in multiple sclerosis
9. Heterogeneity of multiple sclerosis lesions: Implications for the patyhogenesis of demyelination
10. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells
11. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system
12. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis
13. Immune (dys)regulation in multiple sclerosis: Role of the CD95-CD95 ligand system
14. Cell death during autoimmune demyelination: Effector but not target cells are eliminated by apoptosis
15. Defective T cell Fas function in patients with multiple sclerosis
16. Preferential induction of apoptosis by interferon (ifn)-beta compared with ifn-alpha2: Correlation with trail/apo21 induction in melanoma cell lines
17. TGF-beta induces the expression of the FLICE-inhibitory protein and inhibits Fas-mediated apoptosis of microglia
18. Antagonistic effect of IFN-β and IFN-γ on high affinity Fc receptor expression in healthy controls and multiple sclerosis patients
19. Resolution of cutaneous inflammation after local elimination of macrophages